PARP1 and B-cell chronic lymphocytic leukemia: Importantly, RNASEH2B deletions were present in 43% of chronic lymphocytic leukemia (CLL) and 34% of castration-resistant prostate cancers (CRPCs) samples, suggesting these tumors have higher frequency of genome-embedded ribonucleotides and hypersensitivity to PARP inhibitors [54].